Randomised controlled trials in cardiovascular medicine: past achievements, future challengesBMJ 1999; 319 doi: https://doi.org/10.1136/bmj.319.7209.564 (Published 28 August 1999) Cite this as: BMJ 1999;319:564
- Salim Yusuf, professor of cardiology (email@example.com)
- Department of Medicine, McMaster University, Hamilton, Ontario, Canada
- Correspondence to: S Yusuf, Hamilton General Hospital, Hamilton, Ontario L8L 2X2, Canada
- Accepted 30 April 1999
Clinical trials have played a crucial role in the development of treatment strategies for cardiovascular disease: the earliest trials were conducted in the 1950s, but it was not until the 1970-80s that the results of clinical trials had a major impact on the choice of treatments. Relieving symptoms and improving quality of life have always been treatment goals. Over the centuries, the choice of treatment has evolved through several periods (box). The approaches are not necessarily distinct from each other, and current treatment strategies for cardiovascular disease are based on a mixture of goals aimed at the improvement of symptoms (for example, breathlessness), correcting markers of disease (improved ventricular function, etc), and improving clinical outcomes (fewer admissions to hospital, prolonged survival, etc). What characterises the current era is the expectation that theory, observations in animals, and human physiological studies alone are not enough to determine the value of a treatment. Rather, these observations should be verified by providing unequivocal evidence of net clinical benefit on the basis of reliable studies using the methods of randomised controlled trials.
Reliable knowledge (derived from well designed randomised controlled trials) of which treatments do or do not work has become the basis for evidence based practice
Unbiased randomisation is the key methodological basis of randomised controlled trials
Other major methodological advances that make randomised controlled trials efficient are extreme simplicity (which makes large trials feasible) and factorial designs (which enable the testing of more than one hypothesis simultaneously)
Large trials and meta-analyses have both contributed to the reliable evaluation of treatments
Future challenges are the conduct of studies in developing countries and among neglected high risk groups, minimisation of unnecessary bureaucracy, waste, and high costs in conducting trials, and the conduct of more trials of generic issues—for example, population based prevention strategies and other …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial